Curriculum vitae

Name: Djalila Mekahli
Nationality : Belgian
Date of birth: 26/09/76
Born in: Mostaganem - Algeria
Social status: married, 2 children
Email: djalila.mekahli@uzleuven.be
Web : www.AdpedKD.org
https://orcid.org/0000-0003-0954-6088
https://gbiomed.kuleuven.be/pkdresearchgroup
@PKDgroup_Leuven

Institutional responsabilities

1- Staff Member –Clinical Chief
Department of Pediatric Nephrology. UZ Leuven **– Belgium. From Oct 2011**
2- Professor at KU Leuven / Head of PKD research group.
Department of Cellular and Molecular Medicine. KU Leuven**– Belgium. From Sep 2013**
3- Head of Pediatric Residency Program
Department of Pediatrics. UZ Leuven**– Belgium. From Oct 2018**
4- Vice-dean of International Affairs, KU Leuven – **Belgium. From Aug 2024 (elected May)**
5- Co-chair of the National Commission of recognition Pediatrics.
RIZIV/INAMI. **Brussels – Belgium. From 2017**
6- Co-chair of the workgroup for autosomal dominant structural kidney disorders (including ADPKD and TSC) from the European Reference Network for Rare Kidney Diseases (**ERKNet**) (https://erknet.org/index.php?id=39).
7- Initiator and PI of **ADPedKD**: an international web-based database for longitudinal data registry of children with ADPKD (www.adpedkd.org/)
8- Mandate of Senior Clinical Investigator from (The Research Foundation – Flanders - Belgium (FWO) (1804123N) entitled “Translational research into early stages of Autosomal Dominant Polycystic Kidney Disease (ADPKD)”
9- IPNA Clinician Scientist Academy - Mentor

Stay abroad

* Aug 2015-Oct 2015: Visiting Assistant Professor to Yale University. New Heaven, USA
* 2007-2008: Fellowship in pediatric nephrology. **Great Ormond Street Hospital. London, UK**
* 2006 - 2007: Fellowship in pediatric nephrology. **University Hospital Lyon. Lyon , France**

Others

* Member in the ESPN WG IKD.
* Member in the Polycystic Kidney Disease Outcomes Consortium (PKDOC)
* Member in the ongoing development of the new KDIGO clinical practice guideline for the evaluation, management and treatment of ADPKD
* Member of the scientific committee of AIRG-België https://www.airg-belgique.org/nl/wie-zijn-wij/
* Expert reviewer in Orphanet (The portal for rare diseases and orphan drugs) https://www.orpha.net/consor/www/cgi-bin/OC_Exp.php?lng=EN&Expert=730µ
* Core Expert in the c4c Nephrology Expert Group https://conect4children.org/
* Member of EKHA (the European Kidney Health Alliance).
* Academic member of the European ADPKD Forum (EAF).
* Member with PKD International of the first ‘ADPKD Patient Route Map’ – an interactive resource to help patients and families affected by ADPKD. https://pkdinternational.org/adpkd-route-map
* Member of the SONG consortium for pain in ADPKD. https://songinitiative.org/projects/song-pkd/.
* 2024 ICH Good Clinical Practice E6 (R2) certificate (GCP)
* 2021 Fellow of European Society for Paediatric Nephrology (FESPN)
* 2012 **PhD in Biomedical Sciences**, “Autosomal Polycystic Kidney Disease from bedside to bench and back” Doctoral School of Molecular Medicine, KU Leuven **- Belgium**
* 2009 Graduate Diploma of Pediatric Nephrology. KU Leuven. **Leuven - Belgium**
* 2008 Graduate Diploma of Pediatrics. KU Leuven. **Leuven - Belgium**
* 2008 Biomedical Statistics certificate. UCL Institute of Child Health (ICH)-**London – UK**
* 2007 Diplôme inter-universitaire de néphrologie pédiatrique. Lyon University. **Lyon – France**
* 2003 Doctor in medical sciences. KU Leuven. **Leuven - Belgium**

Memberships of scientific societies

* Member of the Belgian Society of Pediatric Nephrology (BPN)
* Member of the European Society of Pediatric Nephrology (ESPN)
* Member of the working group of inherited kidney disease (WGIKD) of ESPN
* Member of the International Pediatric Nephrology Association (IPNA)
* Member of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA).
* Member of European Reference Network for Rare Kidney Diseases (ERKNet).

Web of Science profile

Peer-reviewed publications:	189
Total citations:	4176
H-index:	33

Awards/Valorisation record

- Promotor of a research project fundamental research from FWO (The Research Foundation – Flanders - Belgium): ”Exploring the apelinergic system in autosomal dominant polycystic kidney disease” G060623N of (2023-2027)
- Promotor of 3 consecutive VLAIO grants (a very competitive grant from Flanders Innovation & Entrepreneurship to promote the interaction of pharmaceutical companies and academic researchers Belgium).
    - VLAIO O&O project (2017-2019): Identification of new strategies in the management of ADPKD.
    - VLAIO Innovation mandate of (Post-Doc Jean-Paul Decuypere) (2018-2020): Molecular profiling of early stage ADPKD cellular models for drug development.
    - VLAIO O&O project (2020-2022): Identification of new targets and leads inhibiting cyst formation mechanisms in ADPKD.
- Promotor Industry sponsored study grant of the project entitled ”Identification of early biomarkers and imaging factors for stratification of disease progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD) children” (2021-2024)
- 2019-2023 Co-Promotor Foundation of Scientific Research Flanders (FWO) project: G0C8920N. Ca2+ signalling in ADPKD: mechanisms and consequences**.** (2020-2024)
- 2012 -2016 Copromotor FWO project. “The role of Ca2+ signaling for cyst formation in autosomal dominant polycystic kidney disease”
- 2014-2017 Post-doctoral clinical Research fonds (KOF). University hospitals Leuven.
- 2012-2014 FWO Clinical PhD fellowship (Fund for Scientific Research, Flanders).

Grants

- 2008 Laureate of the Pfizer Educational Grant for promising young physicians. KU Leuven, Promotion 2008.
- 2011 Poster Award at the FASEB Meeting ADPKD
- 2011 2 x Best Presentation Awards ESPN
- 2015 Funding from the Future Fund KOOR of the University Hospitals Leuven
- 2016 ESPN Grant for initiation of the ADPedKD registry
- 2021 ESPN Research Grant for the Evaluation of glucose metabolism in early ADPKD
- 2022 Best Presentation Award ERA
- 2023 Best Presentation Award ESPN
- 2024 Best Abstract ERKNet

Thesis supervisions

* **Promotor of PhD**

1. O. Van Reeth, (PhD student) ongoing: Systemic and cellular glucose metabolism in early stage autosomal dominant polycystic kidney disease (ADPKD).
2. S. De Rechter “Is autosomaal dominante polycystische nierziekte een pediatrische aandoening?”. S. De Rechter obtained a **FWO grant**. **Thesis defense 2018.**
3. P. Janssens “Clinical and fundamental aspects of autosomal polycystic kidney disease”. Co- PhD in collaboration with Martin Wissing (VUB). P. Janssens obtained a **FWO grant**. **Thesis defense 2020.**
4. A. Dachy “Translational characterization of cellular and tissular metabolic perturbations in autosomal dominant polycystic kidney disease”. Co-Phd in collaboration with F. Jouret (ULiège). A. Dachy obtained a FNRS grant. Thesis started in 2020.

* **Co-Promotor of PhD**

1. F. Van Olmen (PhD student) - ongoing: Targeting TRP channels to relief pain.
2. A. Andries “Research into biomarkers for early detection of Autosomal Dominant Polycystic Kidney Disease”. **Thesis defense 2020**.
3. P. Schellekens “Cytopenia in ADPKD: from clinical association to mechanism of disease. **Thesis started 2020**.
4. C. Heinze “Exploring apelinergic system signaling in autosomal dominant polycystic kidney disease”. **Thesis started 2023**.
5. D. Van Giel**:** Analysis of Calcium signaling in autosomal dominant polycystic kidney disease.

* **Evaluator of PhD projects:**

1. Douchy, Thomas (PhD student) ongoing: Contemporary view and new insights in mid – and long term vascular access.
2. Dubois, Antoine (PhD student) ongoing: Unraveling the role of microbiota in the field of intestinal ischemia reperfusion injury and transplantation.
3. Vanneste, Matthias (PhD defense 2023): TRP channels in lower urinary tract function
4. Raaijmakers, Anke: A poor start to life? Perinatal predictors of cardiovascular and renal health in childhood.

List of publications In international peer reviewed journals

1. Zerrouki S, Soyalp G, Taillandier L, Hamida K, Bendib S, Bensid I, Chelih S, **Mekahli D**, Bockenhauer D.
   Renal Fanconi syndrome and vitamin D deficiency: chicken or egg?
   Pediatr Nephrol. 2026 May 2. doi: 10.1007/s00467-026-07347-x. **IF 3.0**
2. Hayakawa H, Tsumura M, Utsumi T, Nihira H, Lei WT, Ogino R, Bucciol G, Nakano T, Amo K, Moriya K, Hayakawa S, Mizoguchi Y, Karakawa S, Lin YN, Shih HP, Lo CC, Janssenswillen S, Van Loo S**, Mekahli D**, Bogunovic D, Boisson-Dupuis S, Izawa K, Ku CL, Yasumi T, Asano T, Meyts I, Okada S.
   Discovering patterns in the pathologic significance of non-missense deleterious variants in RELA.
   J Allergy Clin Immunol. 2026 Mar 13:S0091-6749(26)00074-6. **IF 11.2**
3. Van Reeth OE, Cadnapaphornchai MA, Liebau MC, Earley A, Torres V, Devuyst O, **Mekahli D**.
   KDIGO 2025 ADPKD guideline through pediatric eyes.
   Pediatr Nephrol. 2025 Nov 27. doi: 10.1007/s00467-025-07071-y. **IF 3.0**
4. Massart A, Weekers L, Claes KJ, Van Meerhaeghe T, Snauwaert E, **Mekahli D**, Goffin E, Collard L, Godefroid N, Adams B, Van Cauwelaert S, Van Hoeck K, Block S, Al-Dakkak I, Dahan K, Stordeur P, Vande Walle J.
   Clinical and genetic characteristics of patients diagnosed with atypical hemolytic uremic syndrome (aHUS): epidemiological data from the Belgian cohort of the Global aHUS Registry.
   J Nephrol. 2025 Oct 17;38(9):2841–2850. **IF 2.9**
5. Allegaert K, Macente J, **Mekahli D**, van den Anker J, Annaert P, Smits A.
   Progression of the estimated glomerular filtration rate in asphyxiated neonates undergoing therapeutic hypothermia during the first 10 days of life.
   Pediatr Nephrol. 2025 Dec;41(1):233-238. **IF 3.0**
6. Gimpel C, **Mekahli D**.
   The authors reply.
   Kidney Int. 2025 Sep;108(3):501. **IF 14.8**
7. Keles E, Ali SY, Wintermark P, Annaert P, Groenendaal F, Şahin S, Öncel MY, Armangil D, Koc E, Battin MR, Gunn AJ, Frymoyer A, Chock V, **Mekahli D**, van den Anker J, Smits A, Allegaert K, Bagci U.
   Machine learning based clinical decision tool to predict acute kidney injury and survival in therapeutic hypothermia treated neonates.
   Sci Rep. 2025 May 19;15(1):17278. **IF 4.60**
8. Gimpel C, Fieuws S, Hofstetter J, Pitcher D, Vanmeerbeek L, Haeberle S, Dachy A, Massella L, Seeman T, Ranchin B, Allard L, Bacchetta J, Bayrakci U.S, Becherucci F, Perez-Beltran V, Besouw M, Bialkevich H, Boyer O, Canpolat N, Chauveau D, Çiçek N, Conlon P.J, Devuyst O, Dossier C, Fila M, Flögelová H, Godron-Dubrasquet A, Gokce I, Gonzalez Nguyen-Tang E, González-Rodríguez J.D, Guffens A, Grandaliano G, Heidet L, Jankauskiene A, Levart T.K, Knebelmann B, König J.C, La Scola C, Leone V. F, Leroy V, Litwin M, Lucchetti L, Lungu A.C, Marzuillo P, Mastrangelo A, Miklaszewska M, Montini G, Nobili F, Obrycki L, Papizh S, Paripović A, Paripović D, Peruzzi L, Raes A, Saygili S, Spasojević B, Simon T, Szczepańska M, Trepiccione F, Varda N.M, Westland R, Yüksel S, Zaluska- Lesniewska I, Tenebaum J, Mustafa R, Mallett A.J, Guay-Woodford L.M, Gale D.P, Böckenhauer D, Liebau M.C, Schaefer F, **Mekahli D**, on behalf The RaDaR ADPKD disease group, the ERKReg and the ADPedKD collaborators.
   Insights from ADPedKD, ERKReg and RaDaR registries provide a multi-national perspective on the presentation of childhood autosomal dominant polycystic kidney disease in high- and middle-income countries.
   Kidney international, 2025 Jul;108(1):105-118. **IF 14.8**
9. Cadnapaphornchai MA, Dell KM, Gimpel C, Guay-Woodford LM, Gulati A, Hartung EA, Liebau MC, Mallett AJ, Marlais M, **Mekahli D**, Piccirilli A, Seeman T, Tindal K, Winyard PJD.
   Polycystic Kidney Disease in Children: The Current Status and the Next Horizon.
   Am J Kidney Dis. 2025 Mar 18:S0272-6386(25)00772-3. **IF 13.20**
10. Burgmaier K, Kilian S, Arbeiter K, Atmis B, Boyer O, Buescher A, Dursun I, Erger F, Fila M, Galiano M, Gokce I, Haeffner K, Haffner D, Hooman N, Klaus G, König J, Lange-Sperandio B, Marlais M, Massella L, **Mekahli D**, Miklaszewska M, Miloševski-Lomić G, Obrycki L, Ranchin B, Seitz B, Stabouli S, Tabel Y, Taranta-Janusz K, Weber LT, Weitz M, Wühl E, Yilmaz A, Dötsch J, Schaefer F, Liebau MC; ARegPKD consortium.

A risk score to predict kidney survival in patients with autosomal recessive polycystic kidney disease at the age of two months.
Kidney Int. 2025 Feb 6:S0085-2538(25)00086-9. **IF 14.8**

11. Wigerinck S, Schellekens P, Smith BH, Hanna C, Dachy A, Chedid M, Borghol AH, Senum SR, Bockenhauer D, Harris PC, Jouret F, Bammens B, Chebib FT, **Mekahli D**.
Characteristics of patients with autosomal polycystic kidney disease reaching kidney failure by age 40.
Pediatr Nephrol. 2025 Feb 1. doi: 10.1007/s00467-024-06652-7. **IF 3.0**
12. Kidney Disease: Improving Global Outcomes (KDIGO) ADPKD Work Group.
KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Kidney Int. 2025 Feb;107(2S):S1-S239. **IF 14.8**
13. Torres VE, Ahn C, Barten TRM, Brosnahan G, Cadnapaphornchai MA, Chapman AB, Cornec-Le Gall E, Drenth JPH, Gansevoort RT, Harris PC, Harris T, Horie S, Liebau MC, Liew M, Mallett AJ, Mei C, **Mekahli D**, Odland D, Ong ACM, Onuchic LF, Pei YP, Perrone RD, Rangan GK, Rayner B, Torra R, Balk EM, Gordon CE, Earley A, Mustafa RA, Devuyst O.
KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary.
Kidney Int. 2025 Feb;107(2):234-254. **IF 14.8**
14. Marlais M, **Mekahli D.**
Tuberous sclerosis complex-associated kidney disease in children.
Pediatr Nephrol. 2025 Jan 15. doi: 10.1007/s00467-024-06642-9. **IF 3.0**
15. Rodriguez Mier N, Antoons V, Cuyx S, Santo Ramalho A, Boon M, Proesmans M, **Mekahli D**, Vermeulen F.
Pseudo-Bartter syndrome: A CFTR-related disorder?
J Cyst Fibros. 2024 Oct 31:S1569-1993(24)01799-5. **IF 5.4**
16. Buffin-Meyer B, Richard J, Guigonis V, Weber S, König J, Heidet L, Moussaoui N, Vu JP, Faguer S, Casemayou A, Prakash R, Baudouin V, Hogan J, Alexandrou D, Bockenhauer D, Bacchetta J, Ranchin B, Pruhova S, Zieg J, Lahoche A, Okorn C, Antal-Kónya V, Morin D, Becherucci F, Habbig S, Liebau MC, Mauras M, Nijenhuis T, Llanas B, **Mekahli D**, Thumfart J, Tönshoff B, Massella L, Eckart P, Cloarec S, Cruz A, Patzer L, Roussey G, Vrillon I, Dunand O, Bessenay L, Taroni F, Zaniew M, Louillet F, Bergmann C, Schaefer F, van Eerde AM, Schanstra JP, Decramer S; HNF1B variant study group.
Renal and Extrarenal Phenotypes in Patients With *HNF1B* Variants and Chromosome 17q12 Microdeletions.
Kidney Int Rep. 2024 May 16;9(8):2514-2526. **IF 6.10**
17. Dollfus H, Lilien MR, Maffei P, Verloes A, Muller J, Bacci GM, Cetiner M, van den Akker ELT, Grudzinska Pechhacker M, Testa F, Lacombe D, Stokman MF, Simonelli F, Gouronc A, Gavard A, van Haelst MM, Koenig J, Rossignol S, Bergmann C, Zacchia M, Leroy BP, Mosbah H, Van Eerde AM, **Mekahli D**, Servais A, Poitou C, Valverde D.
Bardet-Biedl syndrome improved diagnosis criteria and management: Inter European Reference Networks consensus statement and recommendations.
Eur J Hum Genet. 2024 Nov;32(11):1347-1360. **IF 5.351**
18. Verjans M, Hindryckx A, Rosier K, Devriendt K, **Mekahli D**, Bockenhauer D. Antenatal presentation and early postnatal treatment of infantile hypercalcemia type 2.
Pediatr Nephrol. 2024 Oct;39(10):2911-2913. **IF 3.0**
19. Dumoulin M, Pottel H, **Mekahli D**, Laenen A, Smits A, Allegaert K.
Pharmacovigilance of nephrotoxic drugs in neonates: the Pottel method for acute kidney injury detection in ELBW neonates.
Pediatr Nephrol. 2024 Aug;39(8):2525-2532. **IF 3.0**
20. **Mekahli D**, Müller RU, Marlais M, Wlodkowski T, Haeberle S, de Argumedo ML, Bergmann C, Breysem L, Fladrowski C, Henske EP, Janssens P, Jouret F, Kingswood JC, Lattouf JB, Lilien M, Maleux G, Rozenberg M, Siemer S, Devuyst O, Schaefer F, Kwiatkowski DJ, Rouvière O, Bissler J.
Clinical practice recommendations for kidney involvement in tuberous sclerosis complex: a consensus statement by the ERKNet Working Group for Autosomal Dominant Structural Kidney Disorders and the ERA Genes & Kidney Working Group.
Nat Rev Nephrol. 2024 Mar 5, s41581-024-00818-0. **IF 41.50**
21. Delafontaine S, Iannuzzo A, Bigley TM, Mylemans B, Rana RR, Baatsen P, Poli MC, Rymen D, Jansen K, **Mekahli D**, Casteels I, Cassiman C, Demaerel P, Lepelley A, Frémond ML, Schrijvers

R, Bossuyt X, Vints K, Huybrechts W, Tacine R, Willekens K, Corveleyn A, Boeckx B, Baggio M, Ehlers L, Munck S, Lambrechts D, Voet AR, Moens L, Bucciol G, Cooper MA, Davis CM, Delon J, Meyts I.
Heterozygous mutations in the C-terminal domain of COPA underlie a complex autoinflammatory syndrome.
Clin Invest. 2024 Jan 4:e163604.**IF 15.90**

22. **Mekahli D**, Guay-Woodford LM, Cadnapaphornchai MA, Goldstein SL, Dandurand A, Jiang H, Jadhav P, Debuque L.
Estimating risk of rapid disease progression in pediatric patients with autosomal dominant polycystic kidney disease: a randomized trial of tolvaptan.
Pediatr Nephrol. 2023 Dec 13. **IF 3.0**
23. Krzyzanski W, Wintermark P, Annaert P, Groenendaal F, Şahin S, Öncel MY, Armangil D, Koc E, Battin MR, Gunn AJ, Frymoyer A, Chock VY, Keles E, **Mekahli D**, van den Anker J, Smits A, Allegaert K.
A Population Model of Time-Dependent Changes in Serum Creatinine in (Near)term Neonates with Hypoxic-Ischemic Encephalopathy During and After
Therapeutic Hypothermia. AAPS J. 2023 Dec 5;26(1):4. **IF 4.5**
24. Demuynck S, Lovinfosse P, Seidel L, Jentjens S, **Mekahli D**, Jouret F, Bammens B, Goffin K.
Standardized 4-point scoring scale of [18F]-FDG PET/CT imaging helps in the diagnosis of renal and hepatic cyst infections in patients with autosomal dominant polycystic kidney disease: a validation cohort.
Clin Kidney J. 2023 Jul 5;16(12):2542-2548. **IF 4.60**
25. Schellekens P, Van Loon E, Coemans M, Meyts I, Vennekens R, Kuypers D, **Mekahli D**, Bammens B.
Leukopenia in autosomal dominant polycystic kidney disease: a single-center cohort of kidney transplant candidates with post-transplantation follow-up.
Clin Kidney J. 2023 Jul 11;16(12):2578-2586. **IF 4.60**
26. Hanna C, Iliuta IA, Besse W, **Mekahli D**, Chebib FT.
Cystic Kidney Diseases in Children and Adults: Differences and Gaps in Clinical Management.
Semin Nephrol. 2023 Nov 22:151434. **IF 3.3**
27. Morello W, Baskin E, Jankauskiene A, Yalcinkaya F, Zurowska A, Puccio G, Serafinelli J, La Manna A, Krzemień G, Pennesi M, La Scola C, Becherucci F, Brugnara M, Yuksel S, **Mekahli D**, Chimenz R, De Palma D, Zucchetta P, Vajauskas D, Drozdz D, Szczepanska M, Caliskan S, Lombet J, Minoli DG, Guarino S, Gulleroglu K, Ruzgiene D, Szmigielska A, Barbi E, Ozcakar ZB, Kranz A, Pasini A, Materassi M, De Rechter S, Ariceta G, Weber LT, Marzuillo P, Alberici I, Taranta-Janusz K, Caldas Afonso A, Tkaczyk M, Català M, Cabrera Sevilla JE, Mehls O, Schaefer F, Montini G.
PREDICT Study Group. Antibiotic Prophylaxis in Infants with Grade III, IV, or V Vesicoureteral Reflux.
N Engl J Med. 2023 Sep 14;389(11):987-997. **IF 158.50**
28. Halawi AA, Burgmaier K, Buescher AK, Dursun I, Erger F, Galiano M, Gessner M, Gökce I, **Mekahli D**, Mir S, Obrycki L, Shroff R, Stabouli S, Szczepanska M, Teixeira A, Weber LT, Wenzel A, Wühl E, Zachwieja K, Dötsch J, Schaefer F, Liebau MC.
Clinical Characteristics and Courses of Patients With Autosomal Recessive Polycystic Kidney Disease-Mimicking Phenocopies.
Kidney Int Rep. 2023 Apr 13;8(7):1449-1454. **IF 6.10**
29. Dachy A, Van Loo L, **Mekahli D**.
Autosomal Dominant Polycystic Kidney Disease in Children and Adolescents: Assessing and Managing Risk of Progression.
Adv Kidney Dis Health. 2023 May;30(3):236-244. **IF 2.67**
30. De Groof J, Dachy A, Breysem L, **Mekahli D**.
Cystic kidney diseases in children.
Arch Pediatr. 2023 May;30(4):240-246. **IF 1.82**
31. Jordens Q, Sevenants L, de Zegher F, **Mekahli D**, Casteels K.
Latrogenic Cushing syndrome in a child due to erroneous compounding of omeprazole containing glucocorticoid: A case report and literature review.
Arch Pediatr. 2023 Mar 27:S0929-693X(23)00025-8. **IF 1.82**
32. Janssens P, Cools W, de Mota N, Decuypere JP, Torres V, Wissing KM, Vennekens R, Bammens B, Llorens-Cortes C, **Mekahli D.**
Apelin is altered in subjects with autosomal dominant polycystic kidney disease and preserved

kidney function.
Nephrol Dial Transplant. 2023 Mar 21:gfad056. **IF 6.10**

33. Schellekens P, Verjans M, Janssens P, Dachy A, De Rechter S, Breysem L, Allegaert K, Bammens B, Vennekens R, Vermeersch P, Pottel H**, Mekahli D**.
Low agreement between various eGFR formulae in pediatric and young adult ADPKD patients.
Pediatr Nephrol. 2023 Mar 20. **IF 3.0**
34. De Bruyne E, Willem L, Van Hoeck K, Reynaert S, Vankerckhove S, Adams B, Leroi S, Collard L, Michaux A, Godefroid N, **Mekahli D**, Knops N, Eloot S, Raes A, Walle JV, Van Hoecke E, Snauwaert E, Levtchenko E.
Illness-related parental stress and quality of life in children with kidney diseases.
Pediatr Nephrol. 2023 Mar 16. **IF 3.0**
35. Breysem L, De Keyzer F, Schellekens P, Dachy A, De Rechter S, Janssens P, Vennekens R, Bammens B, Irazabal MV, Van Ongeval C, Harris PC, **Mekahli D**; CRISP Consortium.
Risk Severity Model for Pediatric Autosomal Dominant Polycystic Kidney Disease Using 3D Ultrasound Volumetry.
Clin J Am Soc Nephrol. 2023 Feb 17. **IF 9.80**
36. **Mekahli D,** Liebau MC, Cadnapaphornchai MA, Goldstein SL, Greenbaum LA, Litwin M, Seeman T, Schaefer F, Guay-Woodford LM.
Design of two ongoing clinical trials of tolvaptan in the treatment of pediatric patients with autosomal recessive polycystic kidney disease.
BMC Nephrol. 2023 Feb 13;24(1):33. **IF 2.30**
37. **Mekahli D**, Guay-Woodford LM, Cadnapaphornchai MA, Greenbaum LA, Litwin M, Seeman T, Dandurand A, Shi L, Sikes K, Shoaf SE, Schaefer F.
Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease: Randomized Controlled Trial.
Clin J Am Soc Nephrol. 2023 Jan 1;18(1):36-46. **IF 9.80**
38. Liebau MC, **Mekahli D**, Perrone R, Soyfer B, Fedeles S.
Polycystic Kidney Disease Drug Development: A Conference Report.
Kidney Med. 2022 Dec 27;5(3):100596. **IF 2.22**
39. Schuermans A, Van den Eynde J, **Mekahli D,** Vlasselaers D.
Long-term outcomes of acute kidney injury in children.
Curr Opin Pediatr. 2022 Nov 15. **IF. 3.60**
40. Allegaert K, **Mekahli D**, Wintermark P, Groenendaal F, Borloo N, Laenen A, Annaert P, Şahin S, Öncel MY, Chock VY, Armangil D, Koc E, Battin MR, Frymoyer A, Keles E, Smits
Rescaling Creatinine Centiles in Neonates Treated with Therapeutic Hypothermia for Neonatal Encephalopathy.
Neonatology. 2022;119(6):792-794. **IF 2.50**
41. Van den Eynde J, Rotbi H, Schuermans A, Hassanabad AF, Gewillig M, Budts W, Kutty S, **Mekahli D**.
Long-Term Consequences of Acute Kidney Injury after Pediatric Cardiac Surgery: A Systematic Review.
J Pediatr. 2022 Sep 9:S0022-3476(22)00795-8. **IF 5.10**
42. **Mekahli D**, Womack H, Dahl NK.
Perspectives on Drug Development in Early ADPKD.
Clin J Am Soc Nephrol. 2022 Aug 23:CJN.05190422. **IF 9.80**
43. Keles E, Wintermark P, Groenendaal F, Borloo N, Smits A, Laenen A, **Mekahli D**, Annaert P, Şahin S, Öncel MY, Chock V, Armangil D, Koc E, Battin MR, Frymoyer A, Allegaert K.
Serum Creatinine Patterns in Neonates Treated with Therapeutic Hypothermia for Neonatal Encephalopathy.
Neonatology. 2022 Jul 7:1-9. **IF 2.50**
44. Dachy A, Decuypere JP, Vennekens R, Jouret F, **Mekahli D**.
Correction to: Is autosomal dominant polycystic kidney disease an early sweet disease?
Pediatr Nephrol. 2022 Sep;37(9):2223-2224. **IF 3.0**
45. Cadnapaphorncha M.A., **Mekahli D**.
Changing the Outcome of a Pediatric Disease: Part II — Clinical Features of ADPKD. Current Treatment Options in Pediatrics, published online 19 may 2022. **IF 0.51**
46. Cadnapaphorncha M.A., **Mekahli D**.
Changing the Outcome of a Pediatric Disease: Part I — Clinical Features of ADPKD. Current Treatment Options in Pediatrics, published online 11 may 2022. **IF 0.51**
47. Janssens P, de Loor H, Decuypere JP, Vennekens R, Llorens-Cortes C, **Mekahli D**, Bammens

B.
On Methods for the Measurement of the Apelin Receptor Ligand Apelin.
Sci Rep. 2022 May 11;12(1):7763. **IF 4.60**

48. Van den Eynde J*, Salaets T*, Louw J, Herman J, Breysem L, Vlasselaers D, Desmet L, Meyns B, Budts W, Gewillig M, **Mekahli D**.
Persistent Markers of Kidney Injury In Children Who Developed Acute Kidney Injury After Pediatric Cardiac Surgery: A Prospective Cohort Study.
J Am Heart Assoc. 2022. In Press. **IF 24.40**
49. Müller RU, Messchendorp AL, Birn H, Capasso G, Gall EC, Devuyst O, van Eerde A, Guirchon P, Harris T, Hoorn EJ, Knoers NVAM, Korst U**, Mekahli D**, Meur YL, Nijenhuis T, Ong ACM, Sayer JA, Schaefer F, Servais A, Tesar V, Torra R, Walsh SB, Gansevoort RT.
An update on the use of tolvaptan for ADPKD: Consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders (WGIKD), the European Rare Kidney Disease Reference Network (ERKNet) and Polycystic Kidney Disease International (PKD-International).
Nephrol Dial Transplant. 2021 Nov 19:gfab312. **IF 6.10**
50. Andries A, Feyaerts A, **Mekahli D**, Van Schepdael A.
Quantification of allantoin and other metabolites of the purine degradation pathway in human plasma samples using a newly developed HILIC-LC-MS/MS method.
Electrophoresis. 2022 Jan 20, 0, 1-9. IF **2.90**
51. Van den Eynde J, Delpire B, Jacquemyn X, Pardi I, Rotbi H, Gewillig M, Kutty S, **Mekahli D**.
Risk factors for acute kidney injury after pediatric cardiac surgery: a meta-analysis.
Pediatr Nephrol. 2022 Mar;37(3):509-519. **IF 3.0**
52. Van den Eynde J, Schuermans A, Verbakel JY, Gewillig M, Kutty S, Allegaert K, **Mekahli D**.
Biomarkers of acute kidney injury after pediatric cardiac surgery: a meta-analysis of diagnostic test accuracy.
Eur J Pediatr. 2022 May;181(5):1909-1921. **IF 5.10**
53. Dachy A, Decuypere JP, Vennekens R, Jouret F, **Mekahli D**.
Is autosomal dominant polycystic kidney disease an early sweet disease?
Pediatr Nephrol. 2022 Jan 5. Online ahead of print. **IF 3.0**
54. Decuypere JP, Van Giel D, Janssens P, Dong K, Somlo S, Cai Y, **Mekahli D**, Vennekens R.
Interdependent Regulation of Polycystin Expression Influences Starvation-Induced Autophagy and Cell Death.
Int J Mol Sci. 2021 Dec 16;22(24):13511. **IF 6.10**
55. Liebau MC, **Mekahli D**.
Translational research approaches to study pediatric polycystic kidney disease.
Mol Cell Pediatr. 2021 Dec 9;8(1):20. **IF 1.184**
56. Burgmaier K, Kilian S, Arbeiter K, Atmis B, Büscher A, Derichs U, Dursun I, Duzova A, Eid LA, Galiano M, Gessner M, Gokce I, Haeffner K, Hooman N, Jankauskiene A, Körber F, Longo G, Massella L, Mekahli D, Miloševski-Lomić G, Nalcacioglu H, Rus R, Shroff R, Stabouli S, Weber LT, Wygoda S, Yilmaz A, Zachwieja K, Zagozdzon I, Dötsch J, Schaefer F, Liebau MC; ARegPKD Consortium.
Early childhood height-adjusted total kidney volume as a risk marker of kidney survival in ARPKD.
Sci Rep. 2021 Nov 4;11(1):21677. **IF 4.60**
57. Van den Eynde J, Rotbi H, Gewillig M, Kutty S, Allegaert K, **Mekahli D**.
In-Hospital Outcomes of Acute Kidney Injury After Pediatric Cardiac Surgery: A Meta-Analysis.
Front Pediatr. 2021 Sep 3;9:733744. **IF 2.60**
58. Van den Eynde J, Cloet N, Van Lerberghe R, Sá MPBO, Vlasselaers D, Toelen J, Verbakel JY, Budts W, Gewillig M, Kutty S, Pottel H, **Mekahli D**.
Strategies to Prevent Acute Kidney Injury after Pediatric Cardiac Surgery: A Network Meta-Analysis.
Clin J Am Soc Nephrol. 2021 Oct;16(10):1480-1490. **IF 9.80**
59. Ekulu PM, Adebayo OC, Decuypere JP, Bellucci L, Elmonem MA, Nkoy AB, **Mekahli D**, Bussolati B, van den Heuvel LP, Arcolino FO, Levtchenko EN.
Novel Human Podocyte Cell Model Carrying G2/G2 APOL1 High-Risk Genotype.
Cells. 2021 Jul 28;10(8):1914. **IF 6.0**
60. Gimpel C, Bergmann C, **Mekahli D**.
Correction to: The wind of change in the management of autosomal dominant polycystic kidney disease in childhood.

Pediatr Nephrol. 2021 Aug 23. **IF 3.0**

61. Morello W, D'Amico F, Serafinelli J, Turroni S, Abati I, Fiori J, Baskin E, Yalcinkaya F, Jankauskiene A, Pennesi M, Zurowska A, Becherucci F, Drozdz D, **Mekahli D**, Krzemien G, La Scola C, Taranta-Janusz K, Mehls O, Schaefer F, Candela M, Montini G.
Low-Dose Antibiotic Prophylaxis Induces Rapid Modifications of the Gut Microbiota in Infants With Vesicoureteral Reflux.
Front. Pediatr. 2021 Jun 17;9:674716**. IF 2.60**
62. Janssens P, Decuypere JP, De Rechter S, Breysem L, Van Giel D, Billen J, Hindryckx A, De Catte L, Baldewijns M, Claes KBM, Wissing KM, Devriendt K, Bammens B, Meyts I, Torres VE, Vennekens R, **Mekahli D**.
Enhanced MCP-1 Release in Early Autosomal Dominant Polycystic Kidney Disease.
Kidney Int Rep. 2021 Apr 6;6(6):1687-1698. **IF 6.10**
63. **Mekahli D.**
The red lipstick mentor.
Pediatr Nephrol. 2021 Aug;36(8):2507-2509. **IF 3.0**
64. Bucciol G, Tousseyn T, Jansen K, Casteels I, Tangye SG, Breuer J, Brown JR, Wollants Van Ranst M, Moens L, **Mekahli D**, Meyts I.
Hematopoietic Stem Cell Transplantation Cures Chronic Aichi Virus Infection in a Patient with X-linked Agammaglobulinemia.
J Clin Immunol. 2021 Aug;41(6):1403-1405. **IF 9.10**
65. Burgmaier K, Brinker L, Erger F, Beck BB, Benz MR, Bergmann C, Boyer O, Collard L, Dafinger C, Fila M, Kowalewska C, Lange-Sperandio B, Massella L, Mastrangelo A, **Mekahli D**, Miklaszewska M, Ortiz-Bruechle N, Patzer L, Prikhodina L, Ranchin B, Ranguelov N, Schild R, Seeman T, Sever L, Sikora P, Szczepanska M, Teixeira A, Thumfart J, Uetz B, Weber LT, Wühl E, Zerres K; ESCAPE Study group; GPN study group, Dötsch J, Schaefer F, Liebau MC; ARegPKD consortium.
Refining genotype-phenotype correlations in 304 patients with autosomal recessive polycystic kidney disease and PKHD1 gene variants.
Kidney Int. 2021 Sep;100(3):650-659. **IF 19.60**
66. Janssens P, Decuypere JP, Bammens B, Llorens-Cortes C, Vennekens R, **Mekahli D**.
The emerging role of the apelinergic system in kidney physiology and disease.
Nephrol Dial Transplant. 2021 Mar 21:gfab070. **IF 6.10**
67. Gimpel C, Bergmann C, **Mekahli D**.
The wind of change in the management of autosomal dominant polycystic kidney disease in childhood.
Pediatr Nephrol. 2022 Mar;37(3):473-487. **IF 3.0**
68. Schellekens P, Roosens W, Meyts I, Vennekens R, Bammens B, **Mekahli D**.
Cytopenia in autosomal dominant polycystic kidney disease (ADPKD): merely an association or a disease- related feature with prognostic implications?
Pediatr Nephrol. 2021 Nov;36(11):3505-3514. **IF 3.0**
69. Dachy A, Collard L, Krzesinski JM, Seghaye MC, Ghuysen MS, **Mekahli D**, Jouret F.
Polykystose rénale autosomique dominante : perspective pédiatrique [Autosomal dominant polycystic kidney disease : a pediatric perspective].
Rev Med Liege. 2020 Dec;75(12):775- 780. **IF 0.30**
70. Andries A, Rozenski J, Vermeersch P, **Mekahli D**, Van Schepdael A.
Recent progress in the LC-MS/MS analysis of oxidative stress biomarkers.
Electrophoresis. 2021 Feb;42(4):402-428. **IF 2.90**
71. Burgmaier K, Ariceta G, Bald M, Buescher AK, Burgmaier M, Erger F, Gessner M, Gokce I, König J, Kowalewska C, Massella L, Mastrangelo A, **Mekahli D**, Pape L, Patzer L, Potemkina A, Schalk G, Schild R, Shroff R, Szczepanska M, Taranta-Janusz K, Tkaczyk M, Weber LT, Wühl E, Wurm D, Wygoda S, Zagozdzon I, Dötsch J, Oh J, Schaefer F, Liebau MC; ARegPKD consortium.
Severe neurological outcomes after very early bilateral nephrectomies in patients with autosomal recessive polycystic kidney disease (ARPKD).
Sci Rep. 2020 Sep 29;10(1):16025. **IF 4.60**
72. Allegaert K, Smits A, **Mekahli D**, van den Anker JN.
Creatinine at Birth Correlates with Gestational Age and Birth Weight: Another Factor of the Imbroglio in Early Neonatal Life.
Neonatology. 2020;117(5):637-640. **IF 2.50**
73. van Donge T, Allegaert K, Gotta V, Smits A, Levtchenko E, **Mekahli D**, van den Anker J,

Pfister M.
Characterizing dynamics of serum creatinine and creatinine clearance in extremely low birth weight neonates during the first 6 weeks of life.
Pediatr Nephrol. 2021 Mar;36(3):649-659. **IF 3.0**

74. Allegaert K, Smits A, van Donge T, van den Anker J, Sarafidis K, Levtchenko E, **Mekahli D**.
Renal Precision Medicine in Neonates and Acute Kidney Injury: How to Convert a Cloud of Creatinine Observations to Support Clinical Decisions.
Front Pediatr. 2020 Jul 28;8:366. **IF 2.60**
75. Cho Y, Tong A, Craig JC, Mustafa RA, Chapman A, Perrone RD, Ahn C, Fowler K, Torres V, Gansevoort RT, Ong ACM, Coolican H, Tze-Wah Kao J, Harris T, Gutman T, Shen JI, Viecelli AK, Johnson DW, Au E, El-Damanawi R, Logeman C, Ju A, Manera KE, Chonchol M, Odland D, Baron D, Pei Y, Sautenet B, Rastogi A, Sharma A, Rangan G; SONG-PKD Workshop Investigators; (**Mekahli D**. as a member of the SONG-PKD Workshop)
Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) Consensus Workshop.
Am J Kidney Dis. 2021 Feb;77(2):255- 263. **IF 13.20**
76. Hanson CS, Craig JC, Logeman C, Sinha A, Dart A, Eddy AA, Guha C, Gipson DS, Bockenhauer D, Yap HK, Groothoff J, Zappitelli M, Webb NJA, Alexander SI, Furth SL, Samuel S, Neu A, Viecelli AK, Ju A, Sharma A, Au EH, Desmond H, Shen JI, Manera KE, Azukaitis K, Dunn L, Carter SA, Gutman T, Cho Y, Walker A, Francis A, Sanchez-Kazi C, Kausman J, Pearl M, Benador N, Sahney S, Tong A; SONG-Kids consensus workshops investigators. (**Mekahli D** – as member of the SONG-Kids consensus workshop).
Establishing core outcome domains in pediatric kidney disease: report of the Standardized Outcomes in Nephrology-Children and Adolescents (SONG-KIDS) consensus workshops.
Kidney Int. 2020 Sep;98(3):553-565. **IF 19.60**
77. Goetschalckx E, **Mekahli D**, Levtchenko E, Allegaert K.
Glomerular Filtration Rate in Former Extreme Low Birth Weight Infants over the Full Pediatric Age Range: A Pooled Analysis.
Int J Environ Res Public Health. 2020 Mar 24;17(6):2144. **IF 4.61**
78. Knops N, Emonds MP, Herman J, Levtchenko E, **Mekahli D**, Pirenne J, Van Geet C, Dierickx Bortezomib for autoimmune hemolytic anemia after intestinal transplantation.
Pediatr Transplant. 2020 Jun;24(4):e13700. **IF 1.30**
79. Janssens P, Jouret F, Bammens B, Liebau MC, Schaefer F, Dandurand A, Perrone RD, Müller RU, Pao CS, **Mekahli D**.
Implications of early diagnosis of autosomal dominant polycystic kidney disease: A post hoc analysis of the TEMPO 3:4 trial.
Sci Rep. 2020 Mar 9;10(1):4294. **IF 4.60**
80. De Rechter S, Bockenhauer D, Guay-Woodford LM, Liu I, Mallett AJ, Soliman NA, Sylvestre LC, Schaefer F, Liebau MC**, Mekahli D**; ADPedKD Consortium.
ADPedKD: A Global Online Platform on the Management of Children With ADPKD.
Kidney Int Rep. 2019 May 29;4(9):1271-1284. **IF 6.10**
81. Burgmaier K, Kilian S, Bammens B, Benzing T, Billing H, Büscher A, Galiano M, Grundmann F, Klaus G, **Mekahli D**, Michel-Calemard L, Milosevski-Lomic G, Ranchin B, Sauerstein K, Schaefer S, Shroff R, Sterenborg R, Verbeeck S, Weber LT, Wicher D, Wühl E, Dötsch J, Schaefer F, Liebau MC.
Clinical courses and complications of young adults with Autosomal Recessive Polycystic Kidney Disease (ARPKD).
Sci Rep. 2019 May 28;9(1):7919. **IF 4.60**
82. Gimpel C, Bergmann C, Bockenhauer D, Breysem L, Cadnapaphornchai MA, Cetiner M, Dudley J, Emma F, Konrad M, Harris T, Harris PC, König J, Liebau MC, Marlais M, **Mekahli D**, Metcalfe AM, Oh J, Perrone RD, Sinha MD, Titieni A, Torra R, Weber S, Winyard PJD, Schaefer F.
International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people.
Nat Rev Nephrol. 2019 Nov;15(11):713-726. **IF 41.50**
83. Schaefer F, **Mekahli D**, Emma F, Gilbert RD, Bockenhauer D, Cadnapaphornchai MA, Shi L, Dandurand A, Sikes K, Shoaf SE.
Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney

disease: rationale and design of a two-part, randomized, double- blind, placebo-controlled trial.
Eur J Pediatr. 2019 Jul;178(7):1013-1021. **IF 5.10**

84. Moens L, Gouwy M, Bosch B, Pastukhov O, Nieto-Patlàn A, Siler U, Bucciol G, **Mekahli D**, Vermeulen F, Desmet L, Maebe S, Flipts H, Corveleyn A, Moshous D, Philippet P, Tangye SG, Boisson B, Casanova JL, Florkin B, Struyf S, Reichenbach J, Bustamante J, Notarangelo LD, Meyts I.
Human DOCK2 Deficiency: Report of a Novel Mutation and Evidence for Neutrophil Dysfunction.
J Clin Immunol. 2019 Apr;39(3):298-308. **IF 9.10**
85. Gimpel C, Avni EF, Breysem L, Burgmaier K, Caroli A, Cetiner M, Haffner D, Hartung EA, Franke D, König J, Liebau MC, **Mekahli D**, Ong ACM, Pape L, Titieni A, Torra R, Winyard PJD, Schaefer F.
Imaging of Kidney Cysts and Cystic Kidney Diseases in Children: An International Working Group Consensus Statement.
Radiology. 2019 Mar;290(3):769-782. **IF 19.70**
86. De Rechter S, Bammens B, Schaefer F, Liebau MC, **Mekahli D**.
Unmet needs and challenges for follow-up and treatment of autosomal dominant polycystic kidney disease: the paediatric perspective.
Clin Kidney J. 2018 Dec;11(Suppl1):i14-i26. **IF 4.60**
87. Bucciol G, Moens L, Payne K, Wollants E, **Mekahli D**, Levtchenko E, Vermeulen F, Tousseyn T, Gray P, Ma CS, Tangye SG, Van Ranst M, Brown JR, Breuer J, Meyts I.
Correction to: Chronic Aichi Virus Infection in a Patient with X-Linked Agammaglobulinemia.
J Clin Immunol. 2018 Nov;38(8):938-939. **IF 9.10**
88. **Mekahli D,** Jouret F.
Copeptin in the Diagnosis of Diabetes Insipidus.
N Engl J Med. 2018 Nov 1;379(18):1784-5. **IF 158.50**
89. Bucciol G, Moens L, Payne K, Wollants E, **Mekahli D**, Levtchenko E, Vermeulen F, Tousseyn T, Gray P, Ma CS, Tangye SG, Van Ranst M, Brown JR, Breuer J, Meyts I.
Chronic Aichi Virus Infection in a Patient with X-Linked Agammaglobulinemia.
J Clin Immunol. 2018 Oct;38(7):748-752. **IF 9.10**
90. Weydert C, Decuypere JP, De Smedt H, Janssens P, Vennekens R, **Mekahli D**.
Fundamental insights into autosomal dominant polycystic kidney disease from human-based cell models.
Pediatr Nephrol. 2019 Oct;34(10):1697-1715. **IF 3.0**
91. Willem L, Knops N, **Mekahli D**, Cochat P, Edefonti A, Verrina E, Groothoff J, Lagae L, Pirenne J, Dobbels F, Borry P, Van Geet C, Levtchenko E.
Renal Replacement Therapy in children with severe developmental disability: guiding questions for decision-making.
Eur J Pediatr. 2018 Dec;177(12):1735-1743. **IF 5.10**
92. Andries A, De Rechter S, Janssens P, **Mekahli D**, Van Schepdael A.
Simultaneous determination of allantoin and adenosine in human urine using liquid chromatography - UV detection.
J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Oct 1;1096:201-207. **IF 3.00**
93. Daenen K, Andries A, **Mekahli D**, Van Schepdael A, Jouret F, Bammens B.
Oxidative stress in chronic kidney disease.
Pediatr Nephrol. 2019 Jun;34(6):975-991. **IF 3.0**
94. Andries A, Daenen K, Jouret F, Bammens B, **Mekahli D**, Van Schepdael A.
Oxidative stress in autosomal dominant polycystic kidney disease: player and/or early predictor for disease progression?
Pediatr Nephrol. 2019 Jun;34(6):993-1008. **IF 3.0**
95. Janssens P, Van Hoeve K, De Waele L, De Rechter S, Claes KJ, Van de Perre E, Wissing KM, Bammens B, Jansen A, **Mekahli D**.
Renal progression factors in young patients with tuberous sclerosis complex: a retrospective cohort study.
Pediatr Nephrol. 2018 Nov;33(11):2085-2093. **IF 3.0**
96. Burgmaier K, Brandt J, Shroff R, Witters P, Weber LT, Dötsch J, Schaefer F, **Mekahli D**, Liebau MC.
Gastrostomy Tube Insertion in Pediatric Patients With Autosomal Recessive Polycystic Kidney Disease (ARPKD): Current Practice.

Front Pediatr. 2018 Jun 4;6:164. **IF 2.60**

97. Burgmaier K, Kunzmann K, Ariceta G, Bergmann C, Buescher AK, Burgmaier M, Dursun I, Duzova A, Eid L, Erger F, Feldkoetter M, Galiano M, Geßner M, Goebel H, Gokce I, Haffner D, Hooman N, Hoppe B, Jankauskiene A, Klaus G, König J, Litwin M, Massella L, **Mekahli D**, Melek E, Mir S, Pape L, Prikhodina L, Ranchin B, Schild R, Seeman T, Sever L, Shroff R, Soliman NA, Stabouli S, Stanczyk M, Tabel Y, Taranta-Janusz K, Testa S, Thumfart J, Topaloglu R, Weber LT, Wicher D, Wühl E, Wygoda S, Yilmaz A, Zachwieja K, Zagozdzon I, Zerres K; ESCAPE Study Group; GPN Study Group, Dötsch J, Schaefer F, Liebau MC; ARegPKD consortium.
Risk Factors for Early Dialysis Dependency in Autosomal Recessive Polycystic Kidney Disease.
J Pediatr. 2018 Aug;199:22-28.e6. **IF 5.10**
98. Bucciol G, Cassiman D, Roskams T, Renard M, Hoffman I, Witters P, Schrijvers R, Schaballie H, Bosch B, Putti MC, Gheysens O, Knops N, Gewillig M, **Mekahli D**, Pirenne J, Meyts I.
Liver transplantation for very severe hepatopulmonary syndrome due to vitamin A-induced chronic liver disease in a patient with Shwachman-Diamond syndrome.
Orphanet J Rare Dis. 2018 May 2;13(1):69. **IF 3.70**
99. Massella L, **Mekahli D**, Paripović D, Prikhodina L, Godefroid N, Niemirska A, Ağbaş A, Kalicka K, Jankauskiene A, Mizerska-Wasiak M, Afonso AC, Salomon R, Deschênes G, Ariceta G, Özçakar ZB, Teixeira A, Duzova A, Harambat J, Seeman T, Hrčková G, Lungu AC, Papizh S, Peco-Antic A, De Rechter S, Giordano U, Kirchner M, Lutz T, Schaefer F, Devuyst O, Wühl E, Emma F.
Prevalence of Hypertension in Children with Early-Stage ADPKD.
Clin J Am Soc Nephrol. 2018 Jun 7;13(6):874-883. **IF 9.80**
100. Verbeeck S, **Mekahli D**, Cassiman D, Maleux G, Witters P.
Long-term outcome of transjugular intrahepatic portosystemic shunt for portal hypertension in autosomal recessive polycystic kidney disease.
Dig Liver Dis. 2018 Jul;50(7):707-712. **IF 4.50**
101. Di Mise A, Tamma G, Ranieri M, Centrone M, van den Heuvel L, **Mekahli D**, Levtchenko EN, Valenti G.
Activation of Calcium-Sensing Receptor increases intracellular calcium and decreases cAMP and mTOR in PKD1 deficient cells.
Sci Rep. 2018 Apr 9;8(1):5704. **IF 4.60**
102. De Rechter S, Breysem L, **Mekahli D**.
Is Autosomal Dominant Polycystic Kidney Disease Becoming a Pediatric Disorder?
Front Pediatr. 2017 Dec 20;5:272. **IF 2.60**
103. Breysem L, De Rechter S, De Keyzer F, Smet MH, Bammens B, Van Dyck M, Hofmans M, Oyen R, Levtchenko E, **Mekahli D**.
3DUS as an alternative to MRI for measuring renal volume in children with autosomal dominant polycystic kidney disease.
Pediatr Nephrol. 2018 May;33(5):827-835. **IF 3.0**
104. De Rechter S, Bacchetta J, Godefroid N, Dubourg L, Cochat P, Maquet J, Raes A, De Schepper J, Vermeersch P, Van Dyck M, Levtchenko E, D'Haese P, Evenepoel P, **Mekahli D.**
Evidence for Bone and Mineral Metabolism Alterations in Children With Autosomal Dominant Polycystic Kidney Disease.
J Clin Endocrinol Metab. 2017 Nov 1;102(11):4210- 4217. **IF 5.80**
105. De Rechter S, Kringen J, Janssens P, Liebau MC, Devriendt K, Levtchenko E, Bergmann C, Jouret F, Bammens B, Borry P, Schaefer F, **Mekahli D**.
Clinicians' attitude towards family planning and timing of diagnosis in autosomal dominant polycystic kidney disease.
PLoS One. 2017 Sep 29;12(9):e0185779. **IF 3.70**
106. Meerschaut I, Rochefort D, Revençu N, Pètre J, Corsello C, Rouleau GA, Hamdan FF, Michaud JL, Morton J, Radley J, Ragge N, García-Miñaúr S, Lapunzina P, Bralo MP, Mori MÁ, Moortgat S, Benoit V, Mary S, Bockaert N, Oostra A, Vanakker O, Velinov M, de Ravel TJ, **Mekahli D**, Sebat J, Vaux KK, DiDonato N, Hanson-Kahn AK, Hudgins L, Dallapiccola B, Novelli A, Tarani L, Andrieux J, Parker MJ, Neas K, Ceulemans B, Schoonjans AS, Prchalova D, Havlovicova M, Hancarova M, Budisteanu M, Dheedene A, Menten B, Dion PA, Lederer D, Callewaert B.

FOXP1-related intellectual disability syndrome: a recognisable entity.
J Med Genet. 2017 Sep;54(9):613-623. **IF 4.00**

107. Van Hoeve K, **Mekahli D**, Morava E, Levtchenko E, Witters P.
Liver involvement in kidney disease and vice versa.
Pediatr Nephrol. 2018 Jun;33(6):957-971. **IF 3.0**
108. Janssens P, Weydert C, De Rechter S, Wissing KM, Liebau MC, **Mekahli D**.
Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
Pediatr Nephrol. 2018 Mar;33(3):395-408. **IF 3.0**
109. Ebner K, Schaefer F, Liebau MC; ARegPKD Consortium, **Mekahli D**.
Recent Progress of the ARegPKD Registry Study on Autosomal Recessive Polycystic Kidney Disease.
Front Pediatr. 2017 Feb 16;5:18.**IF 2.60**
110. van Hoeve K, Vandermeulen C, Van Ranst M, Levtchenko E, van den Heuvel L, **Mekahli D.**
Occurrence of atypical HUS associated with influenza B.
Eur J Pediatr. 2017 Apr;176(4):449- 454. **IF 5.10**
111. **Mekahli D**, van Stralen KJ, Bonthuis M, Jager KJ, Balat A, Benetti E, Godefroid N, Edvardsson VO, Heaf JG, Jankauskiene A, Kerecuk L, Marinova S, Puteo F, Seeman T, Zurowska A, Pirenne J, Schaefer F, Groothoff JW; ESPN/ERA-EDTA Registry.
Kidney Versus Combined Kidney and Liver Transplantation in Young People With Autosomal Recessive Polycystic Kidney Disease: Data From the European Society for Pediatric Nephrology/European Renal Association-European Dialysis and Transplant (ESPN/ERA-EDTA) Registry.
Am J Kidney Dis. 2016 Nov;68(5):782-788. **IF 13.20**
112. Van Horebeek I, Knops N, Van Dyck M, Levtchenko E, **Mekahli D**.
Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature.
Acta Clin Belg. 2017 Jun;72(3):147-155.**IF 1.60**
113. De Rechter S, Levtchenko E, Evenepoel P, **Mekahli D**.
The Case | Hypercalcemia in a child with chronic kidney disease.
Kidney Int. 2016 Jul;90(1):233-4. **IF 19.60**
114. ter Haar E, Labarque V, Tousseyn T, **Mekahli D**.
Severe acute kidney injury as presentation of Burkitt's lymphoma.
BMJ Case Rep. 2016 Apr 26;2016:bcr2016214780. **IF 0.90**
115. Ivanova EA, van den Heuvel LP, Elmonem MA, De Smedt H, Missiaen L, Pastore A, **Mekahli D**, Bultynck G, Levtchenko EN.
Altered mTOR signalling in nephropathic cystinosis.
J Inherit Metab Dis. 2016 May;39(3):457-464. **IF 4.20**
116. Rodrigues KT, **Mekahli D**, Tavares MF, Van Schepdael A.
Development and validation of a CE-MS method for the targeted assessment of amino acids in urine.
Electrophoresis. 2016 Apr;37(7-8):1039-47. **IF 2.90**
117. Bacchetta J, **Mekahli D**, Rivet C, Demède D, Leclerc AL.
Pediatric combined liver-kidney transplantation: a 2015 update.
Curr Opin Organ Transplant. 2015 Oct;20(5):543-9. **IF 2.20**
118. De Rechter S, Decuypere JP, Ivanova E, van den Heuvel LP, De Smedt H, Levtchenko E,
Mekahli D.
Autophagy in renal diseases.
Pediatr Nephrol. 2016 May;31(5):737-52. **IF 3.0**
119. Audrézet MP, Corbiere C, Lebbah S, Morinière V, Broux F, Louillet F, Fischbach M, Zaloszyc A, Cloarec S, Merieau E, Baudouin V, Deschênes G, Roussey G, Maestri S, Visconti C, Boyer O, Abel C, Lahoche A, Randrianaivo H, Bessenay L, **Mekahli D**, Ouertani I, Decramer S, Ryckenwaert A, Cornec-Le Gall E, Salomon R, Ferec C, Heidet L.
Comprehensive PKD1 and PKD2 Mutation Analysis in Prenatal Autosomal Dominant Polycystic Kidney Disease.
J Am Soc Nephrol. 2016 Mar;27(3):722-9. **IF 9.80**
120. Raaijmakers AA, **Mekahli D**, Levtchenko EN.
Simplified screening criteria for HNF1B analysis.

Kidney Int. 2015 Jun;87(6):1258-9. **IF 19.60**

121. Ebner K, Feldkoetter M, Ariceta G, Bergmann C, Buettner R, Doyon A, Duzova A, Goebel H, Haffner D, Hero B, Hoppe B, Illig T, Jankauskiene A, Klopp N, König J, Litwin M, **Mekahli D**, Ranchin B, Sander A, Testa S, Weber LT, Wicher D, Yuzbasioglu A, Zerres K, Dötsch J, Schaefer F, Liebau MC; ESCAPE Study Group; GPN Study Group.
Rationale, design and objectives of ARegPKD, a European ARPKD registry study.
BMC Nephrol. 2015 Feb 18;16:22. **IF 2.30**
122. Brandenburg VM, D'Haese P, Deck A, **Mekahli D**, Meijers B, Neven E, Evenepoel P.
From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD.
Pediatr Nephrol. 2016 Feb;31(2):195-206. **IF 3.0**
123. De Waele L, Lagae L, **Mekahli D**.
Tuberous sclerosis complex: the past and the future.
Pediatr Nephrol. 2015 Oct;30(10):1771-80. **IF 3.0**
124. Raaijmakers A, Corveleyn A, Devriendt K, van Tienoven TP, Allegaert K, Van Dyck M, van den Heuvel L, Kuypers D, Claes K, **Mekahli D**, Levtchenko E.
Criteria for HNF1B analysis in patients with congenital abnormalities of kidney and urinary tract.
Nephrol Dial Transplant. 2015 May;30(5):835-42. **IF 6.10**
125. De Rechter S, De Waele L, Levtchenko E, **Mekahli D.**
Charcot-Marie-Tooth: are you testing for proteinuria?
Eur J Paediatr Neurol. 2015 Jan;19(1):1-5. **IF 3.140**
126. Allegaert K, **Mekahli D**, van den Anker J.
Cystatin C in newborns: a promising renal biomarker in search for standardization and validation.
J Matern Fetal Neonatal Med. 2015;28(15):1833-8. **IF 1.80**
127. Lemmens AS, **Mekahli D**, Devlieger R, Levtchenko E, Allegaert K.
Population-specific serum creatinine centiles in neonates with posterior urethral valves already predict long-term renal outcome.
J Matern Fetal Neonatal Med. 2015 Jun;28(9):1026-31. **IF 1.80**
128. Allegaert K, Vermeersch P, Smits A, **Mekahli D**, Levtchenko E, Pauwels S.
Paired measurement of urinary creatinine in neonates based on a Jaffe and an enzymatic IDMS- traceable assay.
BMC Nephrol. 2014 Apr 15;15:62.**IF 2.30**
129. **Mekahli D**, Ledermann S, Gullett A, Rees L.
Evaluation of quality of life by young adult survivors of severe chronic kidney disease in infancy.
Pediatr Nephrol. 2014 Aug;29(8):1387- 93. **IF 3.0**
130. Allegaert K, Pauwels S, Smits A, Crèvecoeur K, van den Anker J, **Mekahli D**, Vermeersch P.
Enzymatic isotope dilution mass spectrometry (IDMS) traceable serum creatinine is preferable over Jaffe in neonates and young infants.
Clin Chem Lab Med. 2014 Jun;52(6):e107-9. **IF 6.80**
131. Eneman B, **Mekahli D**, Audrezet MP, Lerut E, Van Damme-Lombaerts R, Van den Heuvel L, Levtchenko E.
An unusual presentation of Denys-Drash syndrome due to bigenic disease.
Pediatrics. 2014 Jan;133(1):e252-6. **IF 8.00**
132. **Mekahli D**, Decuypere JP, Sammels E, Welkenhuyzen K, Schoeber J, Audrezet MP, Corvelyn A, Dechênes G, Ong AC, Wilmer MJ, van den Heuvel L, Bultynck G, Parys JB, Missiaen L, Levtchenko E, De Smedt H.
Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin.
Pflugers Arch. 2014 Aug;466(8):1591-604. **IF 4.50**
133. **Mekahli D**, Bacchetta J.
From bone abnormalities to mineral metabolism dysregulation in autosomal dominant polycystic kidney disease.
Pediatr Nephrol. 2013 Nov;28(11):2089-96**. IF 3.0**
134. **Mekahli D**, Parys JB, Bultynck G, Missiaen L, De Smedt H.
Polycystins and cellular Ca2+ signaling.
Cell Mol Life Sci. 2013 Aug;70(15):2697-712. **IF 9.261**

135. **Mekahli D**, Sammels E, Luyten T, Welkenhuyzen K, van den Heuvel LP, Levtchenko EN, Gijsbers R, Bultynck G, Parys JB, De Smedt H, Missiaen L.
Polycystin-1 and polycystin-2 are both required to amplify inositol-trisphosphate-induced Ca2+ release.
Cell Calcium. 2012 Jun;51(6):452-8. **IF 4.30**
136. Allegaert K, Kuppens M, **Mekahli D**, Levtchenko E, Vanstapel F, Vanhole C, van den Anker JN.
Creatinine reference values in ELBW infants: impact of quantification by Jaffe or enzymatic method.
J Matern Fetal Neonatal Med. 2012 Sep;25(9):1678-81. **IF 1.80**
137. George I, **Mekahli D**, Rayyan M, Levtchenko E, Allegaert K.
Postnatal trends in creatinemia and its covariates in extremely low birth weight (ELBW) neonates.
Pediatr Nephrol. 2011 Oct;26(10):1843-9. **IF 3.0**
138. **Mekahli D**, Bultynck G, Parys JB, De Smedt H, Missiaen L.
Endoplasmic-reticulum calcium depletion and disease.
Cold Spring Harb Perspect Biol. 2011 Jun 1;3(6):a004317.**IF 7.20**
139. Sammels E, Devogelaere B, **Mekahli D**, Bultynck G, Missiaen L, Parys JB, De Smedt H.
Unraveling the role of polycystin-2/inositol 1,4,5-trisphosphate receptor interaction in Ca signaling.
Commun Integr Biol. 2010 Nov;3(6):530-2.**IF 2.6**
140. **Mekahli D**, Woolf AS, Bockenhauer D.
Similar renal outcomes in children with ADPKD diagnosed by screening or presenting with symptoms.
Pediatr Nephrol. 2010 Nov;25(11):2275-82. **IF 3.0**
141. Gardeniers SH, **Mekahli D**, Levtchenko E, Lerut E, Renard M, Van Damme-Lombaerts R.
Bone marrow aplasia and graft loss in a pediatric renal transplant patient with polyomavirus nephropathy.
Pediatr Nephrol. 2010 Oct;25(10):2191-2. **IF 3.0**
142. Sammels E, Devogelaere B, **Mekahli D**, Bultynck G, Missiaen L, Parys JB, Cai Y, Somlo S, De Smedt H.
Polycystin-2 activation by inositol 1,4,5-trisphosphate-induced Ca2+ release requires its direct association with the inositol 1,4,5-trisphosphate receptor in a signaling microdomain.
J Biol Chem. 2010 Jun 11;285(24):18794-805. **IF 5.486**
143. **Mekahli D**, Shaw V, Ledermann SE, Rees L.
Long-term outcome of infants with severe chronic kidney disease.
Clin J Am Soc Nephrol. 2010 Jan;5(1):10-7. **IF 9.80**
144. **Mekahli D**, Liutkus A, Fargue S, Ranchin B, Cochat P.
Survey of first-year medical students to assess their knowledge and attitudes toward organ transplantation and donation.
Transplant Proc. 2009 Mar;41(2):634-8. **IF 0.90**
145. **Mekahli D,** Liutkus A, Ranchin B, Yu A, Bessenay L, Girardin E, Van Damme-Lombaerts R, Palcoux JB, Cachat F, Lavocat MP, Bourdat-Michel G, Nobili F, Cochat P.
Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study.
Pediatr Nephrol. 2009 Aug;24(8):1525-32. **IF 3.0**

Publications in national peer reviewed journals

1. Eelen J, Miserez M, **Mekahli D**, Hoffman I. Hirschprung disease and congenital anomalies of the kidney and urinary tract (CAKUT): a genetic disorder or just a coincidence? Belgian Journal of Paediatrics 22(3):126-129, 03 Sep 2020.
2. Smits A, Cattrysse P, **Mekahli D**, Levtchenko E, Thewissen L. Management of neonatal hypertension. Belgian Journal of Paediatrics 22(3): 132-137, 1 Sep 2020
3. De Rechter S, **Mekahli D**. Renale cysten op kinderleeftijd. Percentiel 2016;21:20-3.
4. De Rechter S, **Mekahli D**. Management of Polycystic Kidney Disease from Childhood to Adulthood. Nephrology 4.1, July 2016.
5. De Waele L, **Mekahli D**. Tubereuze Sclerose Complex: beloftevolle toekomstperspectieven.

Percentile tijdschrift voor huisartsen en kinderartsen. 2015.

6. Declercq A, **Mekahli D**, De Waele L, Van Dyck M. Acute abdominal pain in a child with tuberous sclerosis complex and renal polycystosis. Tijdschrift van de Belgische Kinderarts/Journal du Pédiatre Belge. 2014-Vol.16-Nr.3:156-8.
7. Rayyan M, **Mekahli D**, Allegaert K. The Preterm Kidney: Renal Physiology Affects Clinical Pharmacology. Acta Medica Portuguesa 25: 65-67 Oct 2012.
8. **Mekahli D**, Bael A, Hansen P, Thewissen L, Ismaili K. Evidence and pitfalls in the diagnosis and management of antenatally diagnosed renal pelvis dilatation. Tijdschrift van de Belgische Kinderarts/Journal du Pédiatre Belge. 2010-Vol.12-Nr.2:16-8.

Book Chapters

1. Liebau MC, **Mekahli D**. Cystic Kidney Diseases in Children; in Clinical Paediatric Nephrology; Fourth edition, Wallace, Shenoy, and Sinha, in press.
2. Liebau MC, **Mekahli D**, Bergmann C. (2023) Polycystic Kidney Disease: ARPKD and ADPKD; in Pediatric Kidney Disease; 3rd edition, Schaefer, Greenbaum.
3. **Mekahli D**, Cadnapaphornchai MA. Autosomal Dominant Polycystic Kidney Disease in Pediatric Nephrology 8th edition 2022, published at Springer Nature.
4. **Mekahli D**, Liebau M. Cystic kidney diseases. In: Clinical Pediatric Nephrology, 4th edition (Oxford), invited chapter, in preparation.
5. Liebau M, **Mekahli D**, Bergmann C. Polycystic kidney disease: ADPKD & ARPKD. In: Pediatric Kidney Disease (Springer International Publishing), in press.
6. **Mekahli D**, Jouret F (2020) Sclérose tubéreuse de Bourneville. In: Néphrologie de l'enfant (Elsevier Masson), pp. 229-232.
7. **Mekahli D**, Jouret F (2020) Polykystose hépatorénale autosomique dominante. In: Néphrologie de l'enfant (Elsevier Masson), pp. 221-224.
8. **Mekahli D**, Allegaert K (2019) Drug elimination. In: Prescribing Medicines for Children: From drug development to practical administration (Pharmaceutical Press), pp. 31-36.